SolidSeq Colorectal Cancer Panel (71 Genes)

What is Solidseq Colorectal Cancer Panel test?

The Solidseq Colorectal Cancer Panel is a Next Generation Sequencing (NGS)-based test performed on solid tumor tissue (typically FFPE blocks) to detect mutations across 71 genes commonly involved in colorectal cancer. It provides a comprehensive genomic profile of the tumor. This panel detects single nucleotide variants (SNVs), insertions/deletions (indels), copy number variations (CNVs), and gene fusions. It includes key actionable genes like KRAS, NRAS, BRAF, PIK3CA, TP53, and many others relevant for targeted therapy and clinical trials.

Why consider Solidseq Colorectal Cancer Panel test?

• Enables personalized treatment planning by identifying actionable genetic mutations.

• Helps guide the use of targeted therapies, immunotherapies, or clinical trial eligibility.

• Useful in advanced or metastatic cases, where deeper molecular insights can change treatment strategy.

• Offers greater genomic insight compared to limited-gene panels (e.g., KRAS/NRAS/BRAF only).

• Supports prognosis, risk stratification, and monitoring potential resistance mechanisms.

Who should get tested for Solidseq Colorectal Cancer Panel test in Kochi?

This test is suitable for:

• Patients with colorectal cancer (especially advanced/metastatic).

• Those being evaluated for targeted or precision oncology treatments.

• Cases where standard therapy has failed and molecular profiling is needed.

• Oncologists planning second-line therapies or assessing eligibility for experimental treatments/trials.

• Individuals with rare or aggressive tumor behavior, needing detailed mutation analysis.

It usually begins as benign growths called polyps which can become cancerous over time. CRC is one of the most common cancers worldwide. Early detection improves survival significantly. Diagnosis involve Colonoscopy, Fecal occult blood test (FOBT) or fecal immunochemical test (FIT), CT scans, MRI for staging and Molecular tests (e.g., COLORECTAL CANCER PROFILER NEXT) to detect mutations for personalized therapy